Main Office: Loc. Bellaria, 35 - 53018 Sovicille (SI), Italy
e-mail: info@philogen.it – web site: www.philogen.com

Philogen
innovating targeting

Philogen Announces Upcoming Calendar of Corporate Events

Siena, Italy, November 3, 2022 - Philogen S.p.A., a clinical-stage biotechnology company focused on antibody- and small molecule-based therapeutics, announces the calendar of its upcoming corporate events for the remainder of 2022.

9 November 2022

Press Release - Third Quarter Financial Results

1 December 2022

Press Release - Corporate Update

The announcement will be followed by a **Webinar for sell-analysts at 11 am ET / 15 pm GMT / 16 pm CET** on December 1, 2022.

To register to the Webinar, please use the following link, or contact Philogen@consilium-comms.com.

About Philogen

Philogen is a Swiss-Italian clinical-stage company, listed on the Italian stock exchange, engaged in the discovery and development of novel pharmaceutical and biopharmaceutical products. Philogen's strategy is to deliver bioactive agents, for example cytokines or drugs, to the site of disease using antibodies and other ligands that specifically and efficiently target stromal antigens. This technology has generated a strong proprietary pipeline of clinical-stage products and preclinical compounds in an array of disease indications. Philogen is headquartered in Siena, Italy, and has research activities at its subsidiary company Philochem in Zürich, Switzerland. Philogen is independently owned and has signed agreements with several major pharmaceutical companies. For more information, please visit www.philogen.com and www.philochem.com.

For more information please contact:

Philogen

Dr. Emanuele Puca (Investor Relations)

+41 (0) 43 544 88 00

emanuele.puca@philogen.com

Consilium Strategic Communications

Mary-Jane Elliott, Davide Salvi, Lucie Foster

Philogen@consilium-comms.com